AVANIR Reports Additional Data from STAR Phase III of Enrolled ALS Patients

Avanir Pharmaceuticals, Inc. released more data regarding the subset of ALS patients enrolled in its confirmatory Phase 3 STAR trial. This study evaluated two doses of the investigational drug Zenvia compared to placebo in the treatment of patients with pseudobulbar affect (PBA), secondary to ALS or multiple sclerosis. In the ALS patient subset Zenvia met the primary efficacy endpoint by significantly reducing daily PBA episode rates compared to placebo.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail